W STRATEGIES, LLC for ALEXION PHARMACEUTICALS
What was lobbied
2 issue areas, each in the filer's own words, with who lobbied on it and where.
Trade (domestic/foreign) TRD
Monitoring the implementation of the Korea-U.S. Free Trade Agreement, as it relates to transparency in Korean government coverage and reimbursement of biologics.
| Lobbyist | Covered position, as disclosed |
|---|---|
| DARREN WILLCOX | — |
Health Issues HCR
S. 2236: Advancing Breakthrough Therapies for Patients Act. H.R. 5651: Food and Drug Administration Reform Act of 2012. S. 3187: Food and Drug Administration Safety and Innovation Act of 2012. H.R. 4132: Faster Access to Specialized Treatments Act. Federal legislative efforts to enhance the security and integrity of the domestic pharmaceutical distribution system.
| Lobbyist | Covered position, as disclosed |
|---|---|
| DARREN WILLCOX | — |
Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.